Glenmede Trust’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,674
Closed -$87K 2568
2020
Q3
$87K Sell
1,674
-4,336
-72% -$179K ﹤0.01% 1210
2020
Q2
$199K Buy
6,010
+5,149
+598% +$164K ﹤0.01% 1014
2020
Q1
$16K Hold
861
﹤0.01% 2207
2019
Q4
$16K Buy
861
+140
+19% +$2.24K ﹤0.01% 2207
2019
Q3
$9 Buy
721
+359
+99% +$4.33K ﹤0.01% 2417
2019
Q2
$4 Hold
362
﹤0.01% 2714
2019
Q1
$5 Sell
362
-73
-17% -$932 ﹤0.01% 2635
2018
Q4
$4 Buy
+435
New +$6.05K ﹤0.01% 2630
2018
Q2
Sell
-618
Closed -$8K 2442
2018
Q1
$8K Hold
618
﹤0.01% 2271
2017
Q4
$8K Sell
618
-14,340
-96% -$194K ﹤0.01% 2271
2017
Q3
$276K Sell
14,958
-26,921
-64% -$450K ﹤0.01% 1111
2017
Q2
$559K Hold
41,879
﹤0.01% 914
2017
Q1
$559K Buy
+41,879
New +$656K ﹤0.01% 914
2016
Q3
Sell
-119
Closed -$1K 2715
2016
Q2
$1K Sell
119
-23,284
-99% -$240K ﹤0.01% 2501
2016
Q1
$216K Buy
23,403
+119
+0.5% +$1.28K ﹤0.01% 1141
2015
Q4
$345K Hold
23,284
﹤0.01% 1036
2015
Q3
$382K Buy
+23,284
New +$477K ﹤0.01% 1007
2013
Q3
Sell
-1,425
Closed -$21K 2292
2013
Q2
$21K Buy
+1,425
New +$18.8K ﹤0.01% 1715

Glenmede Trust's MNTA Position: Q4 2020 in Review

Glenmede Trust sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,674 shares — an estimated $87K sold.

Glenmede Trust first reported a position in MNTA in Q2 2013 and held it in 18 quarters. The position peaked at $559K in Q2 2017. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Glenmede Trust reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 1,674 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $87K.
  • Glenmede Trust first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
  • Glenmede Trust's Momenta Pharmaceuticals, Inc. position peaked at $559K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.